<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949192</url>
  </required_header>
  <id_info>
    <org_study_id>LYS [2019] 027</org_study_id>
    <nct_id>NCT03949192</nct_id>
  </id_info>
  <brief_title>Efficacy of Kangliuwan for Recurrent Grade IV Glioma</brief_title>
  <official_title>Efficacy of Hospital Traditional Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma: A Prospective Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective Exploratory Clinical Study to explore the efficacy of Hospital Traditional
      Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in tumor volume</measure>
    <time_frame>3 months</time_frame>
    <description>the volume of tumor decreased after taking Kangliuwan</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioma of Brain</condition>
  <condition>Recurrence</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Recurrent grade IV glioma patients and conventional treatment is invalid.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient signed &quot;informed consent&quot; voluntarily;

          2. The age of patient is between 18 and 80 years;

          3. KPS score â‰¥40 ; The patient has normal liver and kidney function Normal heart function
             Better follow-up and compliance;

        Exclusion Criteria:

          1. The patient did not sign &quot;informed consent&quot; or signed unvoluntarily.

          2. Non-glioma patients

          3. Active infection

          4. Human immunodeficiency virus (HIV) positive

          5. Hepatitis C or hepatitis B infective

          6. Pregnancy or breast-feeding women

          7. Patients did not agree to use effective contraception during treatment and the
             following 3 months.

          8. Patients also participated in other clinical studies.

          9. The subjects researchers believe are not suitable for participation or completion of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingtang Lin, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolan Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ling Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of People's Liberation Army (301 hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingtang Lin, MD. Ph.D</last_name>
    <phone>8610-83198362</phone>
    <email>linqingtang@xwhosp.orn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ge Sun, B.A.</last_name>
    <phone>8610-83198362</phone>
    <email>sunge0923@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ge Sun, B.A.</last_name>
      <phone>8610-83168899</phone>
      <email>sunge@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 11, 2019</study_first_submitted>
  <study_first_submitted_qc>May 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Qingtang Lin</investigator_full_name>
    <investigator_title>assistant director physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

